4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
4D Molecular Therapeutics, Inc. (FDMT) is a Biotechnology company based in US with a market capitalization of $594.6M. Revenue grew 230194.6% year-over-year and free cash flow was negative at -$109.6M. This page tracks FDMT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 227 employees · IPO Dec 11, 2020
Valuation
Valuation & price
$9.15as of May 17, 2026· -31.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.18
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$594.6M
Market cap
230194.6%
Revenue growth (YoY)
91.0%
Gross margin
-$109.6M
Free cash flow (USD)
-$381.2M
Net debt
Net cash position
7.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 20, 2026Filing
Clinical Trial Results
- Insider sellJul 14, 2026Filing
Insider Sell $737K · 10b5-1 PlanKirn David · Director, See Remarks · $737.4K
- 8-K eventJun 29, 2026Filing
Debt Financing Agreement
- Insider sellJun 25, 2026Filing
Insider Sell $118KBizily Scott · Chief Legal Officer · $117.7K
- Insider sellJun 23, 2026Filing
Insider Sell $1.2M · 10b5-1 PlanKirn David · Director, See Remarks · $1.2M
- 8-K eventJun 22, 2026Filing
Annual Meeting Results
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- FinancingMay 7, 2026Filing
Securities Registration
Questions
Frequently asked questions
What is 4D Molecular Therapeutics, Inc.'s market cap?
4D Molecular Therapeutics, Inc. (FDMT) has a market capitalization of $594.6M.
What is FDMT's P/E ratio?
A meaningful P/E ratio is not available for FDMT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is FDMT's price-to-book (P/B) ratio?
FDMT trades at 1.18 times book value per share.
Are insiders buying FDMT stock?
SEC Form 4 filings show no open-market insider buys at 4D Molecular Therapeutics, Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.